{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:14:40Z","timestamp":1771629280450,"version":"3.50.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immunocompromised individuals including patients with hematological malignancies constitute a population at high risk of developing severe disease upon SARS-CoV-2 infection. Protection afforded by vaccination is frequently low and the biology leading to altered vaccine efficacy is not fully understood. A patient cohort who had received bone marrow transplantation or CAR-T cells was studied following a 2-dose BNT162b2 mRNA vaccination and compared to healthy vaccine recipients. Anti-Spike antibody and systemic innate responses were compared in the two vaccine cohorts. The patients had significantly lower SARS-CoV-2 Spike antibodies to the Wuhan strain, with proportional lower cross-recognition of Beta, Delta, and Omicron Spike-RBD proteins. Both cohorts neutralized the wildtype WA1 and Delta but not Omicron. Vaccination elicited an innate cytokine signature featuring IFN-\u03b3, IL-15 and IP-10\/CXCL10, but most patients showed a diminished systemic cytokine response. In patients who failed to develop antibodies, the innate systemic response was dominated by IL-8 and MIP-1\u03b1 with significant attenuation in the IFN-\u03b3, IL-15 and IP-10\/CXCL10 signature response. Changes in IFN-\u03b3 and IP-10\/CXCL10 at priming vaccination and IFN-\u03b3, IL-15, IL-7 and IL-10 upon booster vaccination correlated with the Spike antibody magnitude and were predictive of successful antibody development. Overall, the patients showed heterogeneous adaptive and innate responses with lower humoral and reduced innate cytokine responses to vaccination compared to na\u00efve vaccine recipients. The pattern of responses described offer novel prognostic approaches for potentiating the effectiveness of COVID-19 vaccination in transplant patients with hematological malignancies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.899972","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T06:28:47Z","timestamp":1653460127000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Reduced Antibodies and Innate Cytokine Changes in SARS-CoV-2 BNT162b2 mRNA Vaccinated Transplant Patients With Hematological Malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Cristina","family":"Bergamaschi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Pagoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Angel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ifigeneia","family":"Tzannou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margarita","family":"Vlachou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismini","family":"Darmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirah","family":"Ullah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenifer","family":"Bear","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santhi","family":"Devasundaram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Baltadakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Gigantes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George N.","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara K.","family":"Felber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103705","article-title":"Safety and Efficacy of the mRNA BNT162b2 Vaccine Against SARS-CoV-2 in Five Groups of Immunocompromised Patients and Healthy Controls in a Prospective Open-Label Clinical Trial","volume":"74","author":"Bergman","year":"2021","journal-title":"EBioMedicine"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0166","article-title":"How to Provide the Needed Protection From COVID-19 to Patients With Hematologic Malignancies","volume":"2","author":"Ribas","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0142","article-title":"Predictors of Humoral Response to SARS-CoV-2 Vaccination After Hematopoietic Cell Transplantation and CAR T-Cell Therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17841","article-title":"Myeloma Patients With COVID-19 Have Superior Antibody Responses Compared to Patients Fully Vaccinated With the BNT162b2 Vaccine","volume":"196","author":"Gavriatopoulou","year":"2021","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005444","article-title":"Poor Neutralizing Antibody Responses in 106 Patients With WM After Vaccination Against SARS-CoV-2: A Prospective Study","volume":"5","author":"Gavriatopoulou","year":"2021","journal-title":"Blood Adv"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26406","article-title":"Kinetics of Anti-SARS-CoV-2 Neutralizing Antibodies Development After BNT162b2 Vaccination in Patients With Amyloidosis and the Impact of Therapy","volume":"97","author":"Kastritis","year":"2022","journal-title":"Am J Hematol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41408-021-00594-1","article-title":"The Asociacion Vasco-Navarra De Hematologia Y Hemoterapia Cooperative G. Immune Biomarkers to Predict SARS-CoV-2 Vaccine Effectiveness in Patients With Hematological Malignancies","volume":"11","author":"Tamariz-Amador","year":"2021","journal-title":"Blood Cancer J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13578-021-00713-2","article-title":"Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients","volume":"11","author":"Zeng","year":"2021","journal-title":"Cell Biosci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41408-021-00534-z","article-title":"Weak Immunogenicity of SARS-CoV-2 Vaccine in Patients With Hematologic Malignancies","volume":"11","author":"Malard","year":"2021","journal-title":"Blood Cancer J"},{"key":"B10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/s41408-021-00530-3","article-title":"The Neutralizing Antibody Response Post COVID-19 Vaccination in Patients With Myeloma is Highly Dependent on the Type of Anti-Myeloma Treatment","volume":"11","author":"Terpos","year":"2021","journal-title":"Blood Cancer J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01099-x","article-title":"Low Titers of SARS-CoV-2 Neutralizing Antibodies After First Vaccination Dose in Cancer Patients Receiving Checkpoint Inhibitors","volume":"14","author":"Terpos","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26248","article-title":"Comparison of Neutralizing Antibody Responses Against SARS-CoV-2 in Healthy Volunteers Who Received the BNT162b2 mRNA or the AZD1222 Vaccine: Should the Second AZD1222 Vaccine Dose be Given Earlier","volume":"96","author":"Terpos","year":"2021","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients After Allogeneic HCT or CD19-Based CART Therapy-A Single-Center Prospective Cohort Study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.07.012","article-title":"Antibody Response to SARS-CoV-2 Vaccines in Patients With Hematologic Malignancies","volume":"39","author":"Greenberger","year":"2021","journal-title":"Cancer Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2021.10.007","article-title":"Humoral Serological Response to the BNT162b2 Vaccine After Allogeneic Haematopoietic Cell Transplantation","volume":"303","author":"Yeshurun","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-021-01190-3","article-title":"Predictors of Neutralizing Antibody Response to BNT162b2 Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"14","author":"Canti","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737300","article-title":"Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic But Not in Autologous Stem Cell Transplant Recipients","volume":"11","author":"Chiarucci","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine in Haematopoietic Stem Cell Transplantation Recipients","volume":"10","author":"Shem-Tov","year":"2021","journal-title":"Br J Haematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009363","article-title":"Innate Immune Signatures to a Partially-Efficacious HIV Vaccine Predict Correlates of HIV-1 Infection Risk","volume":"17","author":"Andersen-Nissen","year":"2021","journal-title":"PloS Pathog"},{"key":"B21","doi-asserted-by":"publisher","first-page":"109504","DOI":"10.1016\/j.celrep.2021.109504","article-title":"Systemic IL-15, IFN-Gamma, and IP-10\/CXCL10 Signature Associated With Effective Immune Response to SARS-CoV-2 in BNT162b2 mRNA Vaccine Recipients","volume":"36","author":"Bergamaschi","year":"2021","journal-title":"Cell Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1208972109","article-title":"Merck Ad5\/HIV Induces Broad Innate Immune Activation That Predicts CD8(+) T-Cell Responses But Is Attenuated by Preexisting Ad5 Immunity","volume":"109","author":"Zak","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6261","article-title":"Systems Biological Assessment of Immunity to Mild Versus Severe COVID-19 Infection in Humans","volume":"369","author":"Arunachalam","year":"2020","journal-title":"Science"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1688","article-title":"Systems Biology Approach Predicts Immunogenicity of the Yellow Fever Vaccine in Humans","volume":"10","author":"Querec","year":"2009","journal-title":"Nat Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082292","article-title":"Yellow Fever Vaccine Induces Integrated Multilineage and Polyfunctional Immune Responses","volume":"205","author":"Gaucher","year":"2008","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009701","article-title":"Control of SARS-CoV-2 Infection After Spike DNA or Spike DNA+Protein Co-Immunization in Rhesus Macaques","volume":"17","author":"Rosati","year":"2021","journal-title":"PloS Pathog"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26380","article-title":"Distinct Neutralization Profile of Spike Variants by Antibodies Induced Upon SARS-CoV-2 Infection or Vaccination","volume":"97","author":"Rosati","year":"2022","journal-title":"Am J Hematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.793953","article-title":"Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection","volume":"12","author":"Rosati","year":"2021","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2456-9","article-title":"Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals","volume":"584","author":"Robbiani","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 Neutralizing Antibody Activity Using Pseudotyped and Chimeric Viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J Exp Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8121885","article-title":"Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study","volume":"8","author":"Terpos","year":"2020","journal-title":"Microorganisms"},{"key":"B32","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejim.2021.05.010","article-title":"SARS-CoV-2 Antibody Kinetics Eight Months From COVID-19 Onset: Persistence of Spike Antibodies But Loss of Neutralizing Antibodies in 24% of Convalescent Plasma Donors","volume":"89","author":"Terpos","year":"2021","journal-title":"Eur J Intern Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg9873","article-title":"Inflammatory Profiles Across the Spectrum of Disease Reveal a Distinct Role for GM-CSF in Severe COVID-19","volume":"6","author":"Thwaites","year":"2021","journal-title":"Sci Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","article-title":"Plasma Neutralization of the SARS-CoV-2 Omicron Variant","volume":"386","author":"Schmidt","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"rs.3.rs","DOI":"10.21203\/rs.3.rs-1207071\/v1","article-title":"Neutralizing Antibody Titres to SARS-CoV-2 Omicron Variant and Wild-Type Virus in Those With Past Infection or Vaccinated or Boosted With mRNA BNT162b2 or Inactivated CoronaVac Vaccines","author":"Peiris","year":"2022","journal-title":"Res Sq"},{"key":"B36","doi-asserted-by":"publisher","first-page":"s41591","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing Antibodies Against the SARS-CoV-2 Omicron Variant Following Homologous and Heterologous CoronaVac or BNT162b2 Vaccination","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"eabn7591","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA Vaccine-Elicited Human Sera","volume":"18","author":"Muik","year":"2022","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01527-y","article-title":"Safety and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccine Boosters in Healthy Adults: An Interim Analysis","volume":"27","author":"Choi","year":"2021","journal-title":"Nat Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01705-6","article-title":"Neutralizing Antibodies Against the SARS-CoV-2 Delta and Omicron Variants Following Heterologous CoronaVac Plus BNT162b2 Booster Vaccination","volume":"28","author":"Perez-Then","year":"2022","journal-title":"Nat Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems Vaccinology of the BNT162b2 mRNA Vaccine in Humans","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-509143\/v1","article-title":"Impact of BNT162b First Vaccination on the Immune Transcriptome of Elderly Patients Infected With the B.1.351 SARS-CoV-2 Variant","author":"Knabl","year":"2021","journal-title":"Res Sq"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a Third BNT162b2 mRNA COVID-19 Vaccine Dose in Patients With CLL Who Failed Standard Two-Dose Vaccination","volume":"139","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/cancers13174480","article-title":"Poor Neutralizing Antibody Responses in 132 Patients With CLL, NHL and HL After Vaccination Against SARS-CoV-2: A Prospective Study","volume":"13","author":"Terpos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013445","article-title":"Humoral and Cellular Responses After COVID-19 Vaccination in Anti-CD20-Treated Lymphoma Patients","volume":"139","author":"Liebers","year":"2022","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.6030","article-title":"SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments","volume":"8","author":"Parvathaneni","year":"2022","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.899972\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T06:28:50Z","timestamp":1653460130000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.899972\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2022.899972"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.899972","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]},"article-number":"899972"}}